1st Department of Propaedeutic Medicine University of Athens Greece

CEITEC Central European Institute of Technology MasarykBrno Czech Republic

Department of Haematology Royal Bournemouth Hospital Bournemouth UK

Department of Hemato Oncology Belfast City Hospital Belfast UK

Department of Hematology Rigshospitalet Copenhagen Denmark

Department of Hematology Uppsala University Hospital Sweden

Department of Immunology Erasmus MC University Medical Center Rotterdam the Netherlands

Department of Immunology Mayo Clinic Rochester MV USA

Department of Medicine Hematology and Clinical Immunology Branch Padova University School of Medicine Italy

Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet and Hematology Center Karolinska University Hospital Stockholm Sweden

Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

Division of Hematology Department of Medicine Mayo Clinic Rochester MN USA

Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece

Hematology Department and University Pierre et Marie Curie Hopital Pitie Salpetriere Paris France

Hematology Department Nikea General Hospital Piraeus Greece

IMGT® the international ImMunoGeneTics information system® Université de Montpellier Laboratoire d'ImmunoGénétique Moléculaire LIGM Institut de Génétique Humaine IGH UPR CNRS 1142 Montpellier France

Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden

Institute of Applied Biosciences Thessaloniki Greece

Lund University and Hospital Department of Hematology Lund Stem Cell Center Sweden

Molecular Pathology Unit and Haematology Department Niguarda Cancer Center Niguarda Hospital Milan Italy

Strategic Research Program in CLL Division of Experimental Oncology IRCCS San Raffaele Scientific Institute Milan Italy

The Feinstein Institute for Medical Research Northwell Health New York USA

Università Vita Salute San Raffaele Milan Italy

University Hospital Brno Czech Republic

Venetian Institute of Molecular Medicine Padova Italy

Zobrazit více v PubMed

da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6(11):e499. PubMed PMC

Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. PubMed

Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–460. PubMed

Lamanna N, O’Brien S. Novel agents in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):137–145. PubMed PMC

Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16(3):145–162. PubMed

Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1(2):e74–84. PubMed

Baliakas P, Agathangelidis A, Hadzidimitriou A, et al. Not all IGHV3–21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125(5):856–859. PubMed PMC

Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101(8):959–967. PubMed PMC

Zoellner AK, Hohler T, Fries S, et al. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. Ann Hematol. 2016;95(6):853–861. PubMed

Rosenquist R, Bea S, Du MQ, Nadel B, Pan-Hammarstrom Q. Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. J Intern Med. 2017;282(5):371–394. PubMed

Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W. Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations. Leukemia. 2016;30(11):2251–2253. PubMed

Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16): 1921–1924. PubMed PMC

Fischer K, Bahlo J, Fink AM, Goede V, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215. PubMed

Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309. PubMed PMC

Rosenquist R, Ghia P, Hadzidimitriou A, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31(7):1477–1481 PubMed PMC

The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia